Tanyanan Tanawuttiwat1, Brian P O'Neill2, Mauricio G Cohen1, Orawee Chinthakanan3, Alan W Heldman1, Claudia A Martinez1, Carlos E Alfonso1, Raul D Mitrani1, Conrad J Macon4, Roger G Carrillo5, Donald B Williams5, William W O'Neill6, Robert J Myerburg7. 1. Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida. 2. Temple Heart and Vascular Center, Temple University, Philadelphia, Pennsylvania (formerly at Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida). 3. Department of Obstetrics and Gynecology, Chiang Mai University, Chiang Mai, Thailand. 4. Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida. 5. Cardiothoracic Surgery, Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida. 6. Center of Structural Heart Disease, Henry Ford Hospital and Medical Group, Detroit, Michigan. 7. Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: rmyerbur@med.miami.edu.
Abstract
OBJECTIVES: This study sought to determine the incidence of new-onset atrial fibrillation (AF) associated with different methods of isolated aortic valve replacement (AVR)-transfemoral (TF), transapical (TA), and transaortic (TAo) catheter-based valve replacement and conventional surgical approaches. BACKGROUND: The relative incidences of AF associated with the various access routes for AVR have not been well characterized. METHODS: In this single-center, retrospective cohort study, we evaluated a total of 231 consecutive patients who underwent AVR for degenerative aortic stenosis (AS) between March 2010 and September 2012. Patients with a history of paroxysmal, persistent, or chronic AF, with bicuspid aortic valves, and patients who died within 48 h after AVR were excluded. A total of 123 patients (53% of total group) qualified for inclusion. Data on documented episodes of new-onset AF, along with all clinical, echocardiographic, procedural, and 30-day follow-up data, were collated. RESULTS: AF occurred in 52 patients (42.3%). AF incidence varied according to the procedural method. AF occurred in 60% of patients who underwent surgical AVR (SAVR), in 53% after TA-TAVR, in 33% after TAo-TAVR cases, and 14% after TF-TAVR. The episodes occurred at a median time interval of 53 (25th to 75th percentile, 41 to 87) h after completion of the procedure. Procedures without pericardiotomy had an 82% risk reduction of AF compared with those with pericardiotomy (adjusted odds ratio: 0.18; 95% confidence interval: 0.05 to 0.59). CONCLUSIONS: AF was a common complication of AVR with a cumulative incidence of >40% in elderly patients with degenerative AS who underwent either SAVR or TAVR. AF was most common with SAVR and least common with TF-TAVR. Procedures without pericardiotomy were associated with a lower incidence of AF.
OBJECTIVES: This study sought to determine the incidence of new-onset atrial fibrillation (AF) associated with different methods of isolated aortic valve replacement (AVR)-transfemoral (TF), transapical (TA), and transaortic (TAo) catheter-based valve replacement and conventional surgical approaches. BACKGROUND: The relative incidences of AF associated with the various access routes for AVR have not been well characterized. METHODS: In this single-center, retrospective cohort study, we evaluated a total of 231 consecutive patients who underwent AVR for degenerative aortic stenosis (AS) between March 2010 and September 2012. Patients with a history of paroxysmal, persistent, or chronic AF, with bicuspid aortic valves, and patients who died within 48 h after AVR were excluded. A total of 123 patients (53% of total group) qualified for inclusion. Data on documented episodes of new-onset AF, along with all clinical, echocardiographic, procedural, and 30-day follow-up data, were collated. RESULTS:AF occurred in 52 patients (42.3%). AF incidence varied according to the procedural method. AF occurred in 60% of patients who underwent surgical AVR (SAVR), in 53% after TA-TAVR, in 33% after TAo-TAVR cases, and 14% after TF-TAVR. The episodes occurred at a median time interval of 53 (25th to 75th percentile, 41 to 87) h after completion of the procedure. Procedures without pericardiotomy had an 82% risk reduction of AF compared with those with pericardiotomy (adjusted odds ratio: 0.18; 95% confidence interval: 0.05 to 0.59). CONCLUSIONS:AF was a common complication of AVR with a cumulative incidence of >40% in elderly patients with degenerative AS who underwent either SAVR or TAVR. AF was most common with SAVR and least common with TF-TAVR. Procedures without pericardiotomy were associated with a lower incidence of AF.
Authors: Angelo B Biviano; Tamim Nazif; Jose Dizon; Hasan Garan; Mark Abrams; Jessica Fleitman; Dua Hassan; Samir Kapadia; Vasilis Babaliaros; Ke Xu; Josep Rodes-Cabau; Wilson Y Szeto; William F Fearon; Danny Dvir; Todd Dewey; Mathew Williams; Steven Kindsvater; Michael J Mack; John G Webb; D Craig Miller; Craig R Smith; Martin B Leon; Susheel Kodali Journal: J Atr Fibrillation Date: 2017-06-30
Authors: Solomon J Sager; Abdulla A Damluji; Joshua A Cohen; Sachil Shah; Brian P O'Neill; Carlos E Alfonso; Claudia A Martinez; Robert J Myerburg; Alan W Heldman; Mauricio G Cohen; Donald B Williams; Roger G Carrillo Journal: J Interv Card Electrophysiol Date: 2016-05-28 Impact factor: 1.900
Authors: Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir Journal: Cardiol Rev Date: 2016 Mar-Apr Impact factor: 2.644
Authors: Angelo B Biviano; Tamim Nazif; Jose Dizon; Hasan Garan; Jessica Fleitman; Dua Hassan; Samir Kapadia; Vasilis Babaliaros; Ke Xu; Rupa Parvataneni; Josep Rodes-Cabau; Wilson Y Szeto; William F Fearon; Danny Dvir; Todd Dewey; Mathew Williams; Michael J Mack; John G Webb; D Craig Miller; Craig R Smith; Martin B Leon; Susheel Kodali Journal: Circ Cardiovasc Interv Date: 2016-01 Impact factor: 6.546
Authors: Marvin H Eng; Pedro Villablanca; Tiberio Frisoli; Adam B Greenbaum; William W O'Neill Journal: Curr Cardiol Rep Date: 2019-10-31 Impact factor: 2.931